Extended Data Table 1 Patient Characteristics From Part 1 by Dosing Cohort

From: Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

  1. No., number; yr, years. *High risk is defined as patients presenting with abnormality for del(17p) and/or translocation t(4;14) and/or translocation t(14;16). Fluorescence in situ hybridization was performed locally using the individual laboratory’s cut-off values. †Standard risk is defined as patients with absence of abnormality for all of the following: del(17p), translocation t(4;14), and translocation t(14;16). Dose-escalation patients include patients from cohorts 1, 1a, 1b, 1c, 1e, 1f and 2 (Fig. 1).
Back to article page